Henry Schein (HSIC) Q3 Earnings and Revenues Beat Estimates

Henry Schein (HSIC) reported strong Q3 2025 results, with adjusted earnings of $1.38 per share, an 8.66% beat over the $1.27 consensus, and revenues of $3.34 billion, surpassing estimates by 2.02% and up from $3.17 billion year-over-year. Despite these beats, the healthcare products maker's shares have underperformed the S&P 500 year-to-date, declining 6.6% against the index's 16.5% gain. The sustainability of the stock's immediate price movement will hinge on management's commentary, with the stock currently holding a Zacks Rank #3 (Hold).

Analysis

Henry Schein (HSIC) reported strong Q3 2025 results, with adjusted earnings of $1.38 per share, surpassing the Zacks Consensus Estimate of $1.27 by 8.66% and improving from $1.22 year-over-year. Quarterly revenues reached $3.34 billion, exceeding the $3.27 billion consensus by 2.02% and growing from $3.17 billion in the prior year period. This marks the second time in the last four quarters that HSIC has beaten both EPS and revenue estimates.

Despite these positive beats, HSIC shares have significantly underperformed the broader market, declining 6.6% year-to-date compared to the S&P 500's 16.5% gain. The immediate price movement's sustainability is contingent on management's commentary during the upcoming earnings call, as the stock currently holds a Zacks Rank #3 (Hold), indicating expected in-line market performance.

The Medical - Dental Supplies industry, to which HSIC belongs, is favorably positioned within the top 23% of Zacks industries, suggesting a supportive sector environment. Consensus estimates for the coming quarter project EPS of $1.31 on $3.3 billion in revenues, with full fiscal year estimates at $4.82 EPS on $12.98 billion in revenues.

Key Decisions for Investors

• Monitor management's commentary on the earnings call for insights into future guidance and operational outlook, given the stock's year-to-date underperformance despite Q3 beats.
• Evaluate the impact of the favorable Medical - Dental Supplies industry ranking on HSIC's long-term growth prospects, considering the sector's historical outperformance.
• Consider the Zacks Rank #3 (Hold) as an indicator for near-term market-aligned performance, but remain vigilant for changes in earnings estimate revisions following the report.